This resource summarizes important PRP contraindication considerations, medication questions, procedural risks, patient expectations, and informed-consent issues. It is designed for physicians, nurses, practice managers, and aesthetic practices that need clinically useful information and a practical consent workflow.
Designed for orthopedic, sports medicine, pain, hair restoration, facial rejuvenation, microneedling, and other PRP practices.
PRP contraindications are more nuanced than a single checklist. Active infection, significant acute illness, active or unstable malignancy, unexplained blood-count abnormalities, certain hematologic disorders, and conditions at the proposed treatment site may warrant delaying or reconsidering treatment. Other findings may call for individualized clinician or specialist review rather than automatic exclusion.
Current bacterial infection, infection at or near the treatment site, significant systemic illness, and some recent invasive procedures may warrant postponing PRP until the condition has been evaluated or resolved.
Active cancer, current treatment, remission status, malignancy type, and injection location matter. A previous cancer diagnosis should prompt appropriate review rather than a universal lifetime exclusion.
Unexplained cytopenias, abnormal CBC findings, bleeding disorders, or active hematologic disease may alter both procedural risk and the biologic starting material used to prepare PRP.
Some medications affect bleeding risk or platelet function. Medication management should be individualized, and patients should not stop prescribed therapy solely because a generic consent form tells them to do so.
The short answers below are designed for quick review. Open any question for additional clinical context and supporting evidence.
Active bacterial infection generally warrants postponing PRP until the infection has been appropriately treated. Infection at or near the proposed injection site is particularly concerning. Current consensus also considers systemic infection, prolonged antibiotic therapy, immunosuppression, and recent invasive dental care when deciding whether treatment should proceed.
A positive screening response should prompt clinical review rather than an automated decision by a form.
Eymard et al., 2025A history of cancer is not automatically a permanent contraindication to PRP. Active disease, current treatment, remission status, malignancy type, and the proposed injection location should be considered. The GRIIP consensus recommends against injecting PRP in the vicinity of a benign or malignant tumor or metaplastic lesion and supports specialist involvement in selected oncologic situations.
Eymard et al., 2025Not necessarily. A significant or unexplained CBC abnormality should be evaluated before PRP. The 2025 GRIIP consensus states that previously investigated thrombocytopenia above 50,000/mm³, after exclusion of hematologic malignancy, is not by itself a contraindication to PRP injection.
That is separate from another important question: whether the patient's baseline platelet count and collected blood volume provide enough platelets to produce the intended treatment dose.
Anticoagulant or antiplatelet use requires individualized medication and bleeding-risk review. These medications can affect hemostasis and, depending on the agent, platelet biology. However, stopping prescribed therapy can carry important cardiovascular or thromboembolic risk. A generic PRP form should therefore not direct a patient to discontinue a prescribed anticoagulant or antiplatelet medication without appropriate clinical guidance.
Frey et al., 2020 · Narrative review, 2021NSAIDs can affect platelet function, but the effect varies by drug and the clinical significance for PRP remains incompletely defined. Systematic reviews show measurable effects of several nonselective NSAIDs on platelet aggregation, while COX-2-selective agents appear to behave differently. Practices should establish medication protocols appropriate to the procedure and patient rather than applying one universal stop interval to every medication.
Direct evidence establishing the safety of elective PRP procedures during pregnancy or breastfeeding is limited. Available studies of PRP in reproductive medicine do not establish safety for musculoskeletal, dermatologic, or other elective PRP procedures during pregnancy or lactation. Pregnancy, possible pregnancy, and breastfeeding are therefore appropriate screening items for individualized clinician review rather than conditions for an automated website decision.
Cochrane review, 2024 · Masiello et al., 2025Temporary pain, soreness, swelling, or stiffness are among the most commonly reported adverse effects after musculoskeletal PRP injections. Bleeding, bruising, infection, vasovagal reactions, injury to nearby structures, worsening symptoms, and failure to improve are also relevant consent considerations.
A 2026 meta-analysis of 32 randomized trials involving 1,268 PRP-treated knees reported adverse events in 18.7% of PRP cases, most commonly mild knee pain and swelling (10.6%); no severe adverse events were reported in the included trials. These figures apply to intra-articular knee OA studies and should not be presented as universal rates for every PRP procedure.
Nakagawa et al., 2026Aesthetic PRP should include an informed-consent process appropriate to the procedure. Hair restoration, facial rejuvenation, microneedling, and other aesthetic PRP procedures involve treatment-specific risks, expectations, and alternatives that should be discussed with the patient and documented according to applicable professional, institutional, and legal requirements. PRP preparation and aesthetic treatment protocols remain heterogeneous, so standardized or guaranteed cosmetic outcomes should not be implied.
The exact risk discussion should match the procedure and treatment site. A useful consent distinguishes expected transient reactions from less common but clinically important complications, while also addressing the possibility that treatment may not work.
Hair restoration, facial rejuvenation, and microneedling practices may use shorter intake and consent workflows than musculoskeletal clinics. The consent can remain visually concise while still documenting the nature of PRP, procedure-specific risks, alternatives, realistic cosmetic expectations, and the patient's opportunity to ask questions.
The form should avoid guaranteeing hair density, regrowth, permanence, or a specific number of treatments. Treatment response and protocols vary.
Consent should reflect the actual technique being performed and address expected redness, swelling, bruising, discomfort, infection risk, variable cosmetic response, and procedure-specific considerations.
A PRP consent should fit the practice workflow instead of forcing patients to repeat an entire intake. The builder supports three screening approaches.
A PRP consent should document that the patient received understandable information about the proposed treatment, material risks, limitations, reasonable alternatives, and an opportunity to ask questions. A structured form supports that process without turning the patient document into a scientific review.
Evidence: Jeyaraman et al., 2024The builder provides alternate wording for self-pay PRP, variable insurance coverage, procedures that are not submitted to insurance, financial consent handled separately, or no financial statement. Financial acknowledgement remains separate from the patient's medical consent.
The electronic workflow uses large touch targets, short sections, a clear review process, and a final signature step. Clinics can configure their preferred consent template without adding patient-specific information to their saved PRPdose account settings.
This resource is educational and does not provide legal advice. Each practice is responsible for reviewing its final consent language for applicable law, professional standards, institutional policy, payer requirements, and malpractice coverage.
Choose the procedure type, screening workflow, financial language, and level of detail. Common consent elements are included as starting content and can be reviewed and customized by the treating practice.